

RECEIVED  
FEB 24 2003 631

TECH CENTER 1600/2900

Please type a plus sign (+) inside this box ☐

PTO/SB/21 (08-00)  
Approved for use through 10/31/02. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

## TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Total Number Of Pages In This Submission

5

Application Number

09/955,656

Filing Date

September 18, 2001

First Named Inventor

Charles A. Nicolette

Group Art Unit

Not Yet Assigned

Examiner Name

Not Yet Assigned

Attorney Docket No.

GZ 2096.00

### ENCLOSURES (check all that apply)

- |  |  |   |
|--|--|---|
| <input type="checkbox"/> Fee Transmittal Form  | <input type="checkbox"/> Assignment Papers<br>(for an Application)                         | <input type="checkbox"/> After Allowance Communication to Group                               |
| <input type="checkbox"/> Fee Attached  | <input type="checkbox"/> Drawing(s)  | <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences           |
| <input type="checkbox"/> Amendment / Reply   | <input type="checkbox"/> Licensing-related Papers  | <input type="checkbox"/> Appeal Communication to Group<br>(Appeal Notice, Brief, Reply Brief) |
| <input type="checkbox"/> After Final   | <input type="checkbox"/> Petition  | <input type="checkbox"/> Proprietary Information  |
| <input type="checkbox"/> Affidavits/declarations   | <input type="checkbox"/> Petition to Convert to a Provisional Application                  | <input type="checkbox"/> Status Letter  |
| <input type="checkbox"/> Extension of Time Request   | <input type="checkbox"/> Power of Attorney, Revocation<br>Change of Correspondence Address | <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below):               |
| <input type="checkbox"/> Express Abandonment Request   | <input type="checkbox"/> Terminal Disclaimer   | 7 references and Return Receipt Postcard  |
| <input checked="" type="checkbox"/> Supplemental Information Disclosure Statement w/PTO 1449 | <input type="checkbox"/> Request for Refund  |   |
| <input type="checkbox"/> Certified Copy of Priority Document(s)                              | <input type="checkbox"/> CD, Number of CD(s) _____   |   |
| <input type="checkbox"/> Response to Missing Parts/<br>Incomplete Application                | Remarks  |   |
| <input type="checkbox"/> Response to Missing Parts<br>under 37 CFR 1.52 or 1.53              |  |   |

### SIGNATURE OF APPLICANT, ATTORNEY OR AGENT

Firm  
or  
Individual Name

Antoinette F. Konski  
Bingham McCutchen LLP  
Three Embarcadero Center, Suite 1800  
San Francisco, California 94111

Signature

*Antoinette Konski*

Date

Feb. 11, 2003


### CERTIFICATE OF MAILING

I hereby certify that this paper or fee is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231 on this date: February 12, 2003

*Peggy Nichols*

Peggy Nichols

Burden Hours Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Box Patent Application, Washington, DC 20231.



PATENT  
Docket No. GZ 2096.00

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

<b>CERTIFICATE OF MAILING BY "FIRST CLASS MAIL"</b>	
I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231 on February 12, 2003.	
<i>Peggy Nichols</i>	Name of Person signing: Peggy Nichols

**RECEIVED**  
FEB 24 2003  
TECH CENTER 1600/2900  
#6  
Plunkett  
3/3/03

In re Application for:

Charles A. NICOLETTE, et al.

Serial No.: 09/955,656

Filing Date: September 18, 2001

For: METHOD TO IDENTIFY ANTIBODY  
TARGETS

Examiner: Unassigned

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT  
UNDER 37 C.F.R. § 1.97**

Commissioner for Patents  
Washington, D.C. 20231

Dear Sir:

Pursuant to 37 C.F.R. § 1.97 and § 1.98, Applicant submits for consideration in the above-identified application the documents listed on the attached Form PTO-1449. Copies of the documents are attached. The Examiner is requested to make these documents of record.

This Supplemental Information Disclosure Statement is submitted:

- ☒ Within three months of the application filing date or before receipt of a first Office Action on the merits; accordingly, no fee or separate requirements are required.
- ☐ After receipt of a first Office Action on the merits but before a final Office Action or Notice of Allowance.
  - ☐ A fee is required. A check in the amount of \$\* is enclosed.
  - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided below; according, no fee is believed to be due.
- ☐ After receipt of a final Office Action or Notice of Allowance, but before payment of the issue fee. Accordingly, a Petition requesting consideration of the Information Disclosure Statement, an authorization to charge our deposit account, and a Certification under 37 C.F.R. § 1.97(e) are provided herein.

Applicant would appreciate the Examiner initialing and returning the Form PTO-1449A and 1449 B, indicating that the information has been considered and made of record herein.

This Supplemental Information Disclosure Statement under 37 C.F.R. § 1.97 is not to be construed as a representation that: (i) a complete search has been made; (ii) additional information material to the examination of this application does not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the above information constitutes prior art to the subject invention.

In the unlikely event that the transmittal letter is separated from this document and the U.S. Patent Office determines that an extension and/or other relief is required, Applicant petitions for any required relief including extensions of time and authorizes the Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to **Deposit Account No. 50-2518** referencing billing no.:219442-7240. However, the Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.

Effective July 1, 2002, the firms of McCutchen, Doyle, Brown & Enersen, LLP and Bingham Dana LLP merged to become Bingham McCutchen LLP.

Respectfully submitted,

Dated: Feb. 11, 2003

By: Antoinette F. Konski  
Antoinette F. Konski  
Registration No. 34,202

Bingham McCutchen LLP  
Formerly McCutchen, Doyle, Brown & Enersen, LLP  
Three Embarcadero Center, Suite 1800  
San Francisco, California 94111  
Telephone: (650) 849-4950  
Facsimile: (650) 849-4800

Form PTO-1449	Docket No. GZ 2096.00	Appl. No. 09/955,656
INFORMATION DISCLOSURE STATEMENT	Applicant(s) Charles A. NICOLETTE, et al.	
	Filing Date: September 18, 2001	Group Art Unit: Not Yet Assigned
(use several sheets if necessary)		

## U.S. PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date (if appropriate)
							RECEIVED
							FEB 24 2003

## FOREIGN PATENT DOCUMENTS

TECH CENTER 1600/2900

Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Translation YES NO
	1.	02/14/02	WO 02/12899	Biovation Ltd., et al			

## OTHER DOCUMENTS

(including author, title, date, pertinent pages, etc.)

Examiner Initials	Ref. No.	Title
	2.	Jurinke Christian, et al.: "Application of nested PCR and mass spectrometry for DNA-based virus detection: HBV-DNA detected in the majority of isolated anti-HBc positive sera." GENETIC ANALYSIS BIOMOLECULAR ENGINEERING, vol. 14, no. 3, January 1998 (1998-01), pages 97-102.
	3.	Galea P., et al.: "Rationale for a vaccine using cellular-derived epitope presented by HIV isolates" VACCINE, BUTTERWORTH SCIENTIFIC. GUILDFORD, GB, vol. 17, no. 13-14, January 1999 (1999-01), pages 1700-1705.
	4.	Sickmann A., et al.: "Identification of major histocompatibility complex class II-associated peptides derived from freshly prepared rat Langerhans cells using MALDI-PSD and Edman degradation." THE ANALYST. ENGLAND APR 2000, vol. 125, no. 4, April 2000 (2000-04), pages 569-573.
	5.	Peter Jochen, et al.: "Analysis of free prostate-specific antigen (PSA) after chemical release from the complex with alpha1-antichymotrypsin (PSA-ACT)." CLINICAL CHEMISTRY, vol. 46, no. 4, April 2000 (2000-04), pages 474-482.
	6.	Jungblut Peter, R., et al.: "Proteomics in human disease: Cancer, heart and infectious diseases." ELECTROPHORESIS, vol. 20, no. 10, July 1999 (1999-07), pages 2100-2110.
	7.	Chaurand P., et al.: "Peptide and protein identification by matrix-assisted laser desorption ionization (MALDI) and MALDI-post-source decay time-of-flight mass spectrometry" JOURNAL OF THE AMERICAN SOCIETY FOR MASS SPECTROMETRY, ELSEVIER SCIENCE INC., NEW YORK, NY, US, vol. 10, no. 2, February 1999 (1999-02), pages 91-103.

EXAMINER:	DATE CONSIDERED:
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.	